Banner Publications MH200828 N141

Publications

Results found: 94

Showing results: 1 - 50

Nature communications

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

09-09-2020
Key
bioRxiv

Human Prostate Cancer-Associated Macrophage Subtypes and Prognostic Potential Revealed by Single-cell Transcriptomics

20-06-2020
Key
Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022
Clinica chimica acta; international journal of clinical chemistry

Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.

29-11-2022
Urologic oncology

Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.

12-11-2022
European urology oncology

Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.

10-11-2022
Prostate cancer and prostatic diseases

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

12-10-2022
Endocrinology

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

11-10-2022
Clinical chemistry and laboratory medicine

Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.

27-09-2022
Advances in experimental medicine and biology

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

16-09-2022
Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022
Drugs - real world outcomes

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.

01-06-2022
Cancer chemotherapy and pharmacology

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

01-06-2022
Clinical epigenetics

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

04-05-2022
Clinical genitourinary cancer

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

01-04-2022
Clinical genitourinary cancer

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.

01-02-2022
Prostate cancer and prostatic diseases

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

01-02-2022
Cell reports

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

14-12-2021
Journal of palliative medicine

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.

01-12-2021
Nature communications

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

04-11-2021
Trials

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.

04-11-2021
Clinica chimica acta; international journal of clinical chemistry

Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.

01-10-2021
Molecular cancer research : MCR

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

01-10-2021
Nature cell biology

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

01-09-2021
Prostate cancer and prostatic diseases

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.

01-09-2021
Cancers

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.

27-08-2021
Cancer reports (Hoboken, N.J.)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.

01-08-2021
European urology oncology

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

01-08-2021
Molecular oncology

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

01-07-2021
Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021
European urology focus

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.

01-07-2021
Cancer chemotherapy and pharmacology

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.

01-06-2021
Genome biology

Functional mapping of androgen receptor enhancer activity.

11-05-2021
Future oncology (London, England)

The intravenous to oral switch of taxanes: strategies and current clinical developments.

01-04-2021
Nature communications

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.

15-01-2021
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.

01-01-2021
European urology

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

01-12-2020
JAMA network open

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.

01-10-2020
BMC cancer

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

14-09-2020
International journal of cancer

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

15-08-2020
Nature genetics

Prostate cancer reactivates developmental epigenomic programs during metastatic progression.

01-08-2020
Nucleosides, nucleotides & nucleic acids

Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.

31-07-2020
Future oncology (London, England)

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.

01-07-2020
Prostate cancer and prostatic diseases

Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.

01-06-2020
European journal of cancer (Oxford, England : 1990)

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.

01-05-2020
Clinical genitourinary cancer

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.

01-02-2020
Endocrine-related cancer

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

01-02-2020
eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019
Cancer cell

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.

09-12-2019
Pharmacotherapy

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.

01-12-2019

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.